drug target for asthmaWatch
For asthma and COPD we want to achieve a more local effect rather than systemic, for a systemic effect we'd target the alveolar sacs but for a local effect what would be the target location? Would it be the bronchi and bronchioles in the conducting zone?
That is also where parasympatholytics like ipratropium (short-acting M3 muscarinic-receptor antagonist) and tiotropium (long-acting M3 muscarinic-receptor antagonist) work, although they work by decreasing the synthesis of IP3, and as such, limit smooth muscle contraction, and thus, reduce bronchoconstriction.
Hope this helps.